Norman Schwartz

Director at Syncromune.

Raised on Syncromune filings

$144.8M

of $144.8M offered across 1 Form D filing

Form D filings: 1
Teammates: 9
Last filing: May 11, 2026

Company

Biotech · Fort Lauderdale, FL

Cryoablation-based immunotherapy for prostate cancer

Cryoablation-based immunotherapy for prostate cancer

Investors: 77

Investors: 77
Sector: Biotech
HQ: Fort Lauderdale, FL

Syncromune filings

Syncromune Form D filings
Filed	Security	Sold of offered	Filing
May 11, 2026	Equity	$144.8M/ $144.8M	Form D/A

EquityFiled May 11, 2026Form D/A
$144.8M/ $144.8M

Works with

Also named on Syncromune filings

Eamonn HobbsChief Executive Officer, Form D signerForm D signer Jeffrey ClelandDirector Stephen DaleExecutive Officer Charles J. LinkExecutive Officer, Director Douglas G. WatsonDirector Joseph C. MaroonDirector Kerri-Ann MillarExecutive Officer Agustin GagoExecutive Officer Joseph GerardiExecutive Officer